Free Trial

Lancashire (LRE) Competitors

Lancashire logo
GBX 574.68 +0.68 (+0.12%)
As of 05:44 AM Eastern

LRE vs. MDC, CCT, ROAD, PRIM, EME, CCS, GEO, PHM, J, and MTH

Should you be buying Lancashire stock or one of its competitors? The main competitors of Lancashire include Mediclinic International (MDC), The Character Group (CCT), Roadside Real Estate (ROAD), Primorus Investments (PRIM), Empyrean Energy (EME), Crossword Cybersecurity (CCS), Georgian Mining (GEO), Phimedix Plc (PHM.L) (PHM), Jacobs Engineering Group (J), and Mithras Investment Trust (MTH). These companies are all part of the "construction" industry.

Lancashire vs.

Mediclinic International (LON:MDC) and Lancashire (LON:LRE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.

Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 3.1%. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire pays out 34.3% of its earnings in the form of a dividend. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio.

Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Mediclinic International4.99% 5.50% 2.30%
Lancashire 37.12%10.76%6.75%

Lancashire received 115 more outperform votes than Mediclinic International when rated by MarketBeat users. However, 57.33% of users gave Mediclinic International an outperform vote while only 44.53% of users gave Lancashire an outperform vote.

CompanyUnderperformOutperform
Mediclinic InternationalOutperform Votes
219
57.33%
Underperform Votes
163
42.67%
LancashireOutperform Votes
334
44.53%
Underperform Votes
416
55.47%

Lancashire has lower revenue, but higher earnings than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mediclinic International£3.38B0.00£169M£0.23N/A
Lancashire£536.12M3.23£199.02M£52.4910.95

In the previous week, Lancashire had 7 more articles in the media than Mediclinic International. MarketBeat recorded 7 mentions for Lancashire and 0 mentions for Mediclinic International. Lancashire's average media sentiment score of 0.17 beat Mediclinic International's score of 0.00 indicating that Lancashire is being referred to more favorably in the news media.

Company Overall Sentiment
Mediclinic International Neutral
Lancashire Neutral

39.2% of Mediclinic International shares are held by institutional investors. Comparatively, 60.5% of Lancashire shares are held by institutional investors. 48.9% of Mediclinic International shares are held by company insiders. Comparatively, 0.6% of Lancashire shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mediclinic International has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Lancashire has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Lancashire has a consensus target price of GBX 788.75, suggesting a potential upside of 37.25%. Given Lancashire's stronger consensus rating and higher probable upside, analysts plainly believe Lancashire is more favorable than Mediclinic International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mediclinic International
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Lancashire
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Lancashire beats Mediclinic International on 15 of the 19 factors compared between the two stocks.

Remove Ads
Get Lancashire News Delivered to You Automatically

Sign up to receive the latest news and ratings for LRE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LRE vs. The Competition

MetricLancashireInsurance IndustryFinancial SectorLON Exchange
Market Cap£1.73B£2.93B£4.28B£2.60B
Dividend Yield0.19%1.22%4.18%4.95%
P/E Ratio10.955.5415.98140.53
Price / Sales3.23121.731,685.03279,984.68
Price / Cash2.172.0448.9727.96
Price / Book0.941.433.374.61
Net Income£199.02M£474.99M£1.27B£5.78B
7 Day Performance1.53%0.47%0.56%0.19%
1 Month Performance-4.54%-0.16%6.75%5.19%
1 Year Performance-7.68%2.29%11.01%127.33%

Lancashire Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LRE
Lancashire
3.9708 of 5 stars
GBX 574.68
+0.1%
GBX 788.75
+37.3%
-8.5%£1.73B£536.12M10.95393Insider Trade
News Coverage
MDC
Mediclinic International
N/AN/AN/AN/A£3.69B£3.38B2,178.261,640
CCT
The Character Group
N/AGBX 259.80
-1.6%
N/A+3.4%£48.02M£116.84M9.201,540Dividend Increase
News Coverage
ROAD
Roadside Real Estate
N/AGBX 31
-1.6%
N/AN/A£42.93M£416,200.570.993,790
PRIM
Primorus Investments
N/AGBX 3.33
-4.9%
N/A-30.7%£4.65MN/A5.0212,800High Trading Volume
EME
Empyrean Energy
N/AGBX 0.11
-0.9%
N/A-77.4%£4.41MN/A-0.0535,500
CCS
Crossword Cybersecurity
N/AN/AN/AN/A£1.95M£4.19M-43.751,540Gap Down
High Trading Volume
GEO
Georgian Mining
N/AN/AN/A-91.3%£1.94M£232,997.00-0.2015,800Gap Down
PHM
Phimedix Plc (PHM.L)
N/AN/AN/AN/A£327,000.00N/A-1.586,520Gap Down
High Trading Volume
J
Jacobs Engineering Group
N/AN/AGBX 200
+∞
N/A£0.00N/A0.0060,000News Coverage
High Trading Volume
MTH
Mithras Investment Trust
N/AN/AN/AN/A£0.00N/A0.001,920Gap Up
Remove Ads

Related Companies and Tools


This page (LON:LRE) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners